Segment Information (Schedule of Total Revenues of Top Selling Products) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014 drug		Mar. 31, 2013
Revenue, Major Customer [Line Items]
Revenues	$ 289,084		$ 290,196
Number of other insignificant generic drugs	80
Par Pharmaceutical [Member]
Revenue, Major Customer [Line Items]
Revenues	273,806		272,800
Par Pharmaceutical [Member] | Budesonide (Entocort EC) [Member]
Revenue, Major Customer [Line Items]
Revenues	37,349		50,403
Par Pharmaceutical [Member] | Propafenone Rythmol Sr [Member]
Revenue, Major Customer [Line Items]
Revenues	21,112		17,159
Par Pharmaceutical [Member] | Divalproex (Depakote) [Member]
Revenue, Major Customer [Line Items]
Revenues	20,405		1,426
Par Pharmaceutical [Member] | Bupropion Er Wellbutrin [Member]
Revenue, Major Customer [Line Items]
Revenues	16,342		8,253
Par Pharmaceutical [Member] | Metoprolol Succinate ER (Toprol-XL) [Member]
Revenue, Major Customer [Line Items]
Revenues	14,117		19,401
Par Pharmaceutical [Member] | Other [Member]
Revenue, Major Customer [Line Items]
Revenues	145,631		98,402
Par Pharmaceutical [Member] | Other product related royalty streams [Member]
Revenue, Major Customer [Line Items]
Revenues	5,439	[1]	6,779	[1]
Strativa [Member]
Revenue, Major Customer [Line Items]
Revenues	15,278		17,396
Strativa [Member] | Megace ES [Member]
Revenue, Major Customer [Line Items]
Revenues	8,154		10,536
Strativa [Member] | Nascobal Nasal Spray [Member]
Revenue, Major Customer [Line Items]
Revenues	6,324		6,202
Strativa [Member] | Other [Member]
Revenue, Major Customer [Line Items]
Revenues	(12)		(241)
Strativa [Member] | Other product related royalty streams [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 812	[1]	$ 899	[1]

[1] Other product related revenues represents licensing and royalty related revenues from profit sharing agreements.